Mukhammadyusuf Shkuratovich Abdykadyrov

Dr. Mukhammadyusuf Shkuratovich Abdykadyrov

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in Clinical Medicine (Russian Journal)
Verified
Journal Article
Closed access
PDF file
FYF. A. Yusupov
F. A. Yusupov
IYI. T. Ydyrysov
I. T. Ydyrysov
MAM. Sh. Abdykadyrov
M. Sh. Abdykadyrov
TYT. F. Yusupova
T. F. Yusupova
Parkinson’s disease (PD) affects men and women differently, creating unique challenges and approaches in its treatment. Men are twice as likely to develop PD as women, but women experience higher mortality rates and faster disease progression. Moreover, motor and non-motor symptoms, response to treatment, and risk factors differ between men and women. These differences support the hypothesis that the disease’s pathogenesis may involve different mechanisms in male and female patients, or the same mechanisms manifesting differently. This review summarizes current knowledge on gender differences in the clinical manifestations of PD, risk factors, treatment response, and the disease’s pathophysiological mechanisms. Understanding how the pathology differently affects men and women can aid in the development of individualized interventions and innovative programs to meet the varied needs of patients of both sexes, thereby improving the quality of care.

5 August 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
FYF.A. Yusupov
F.A. Yusupov
AIAkmal Iuldashev
Akmal Iuldashev
MAM.SH. Abdykadyrov
M.SH. Abdykadyrov
TYT.F. Yusupova
T.F. Yusupova
Numerous studies showed an association between Parkinson’s disease and low uric acid levels. Low uric acid levels are associated with an increased risk of Parkinson’s disease, its progression, and the severity of symptoms. Although the biological mechanisms for this association have not yet been established, it is suggested that uric acid acts as an antioxidant, reducing oxidative stress and protecting dopaminergic neurons. However, some recent studies question this hypothesis. The article discusses the biological properties of uric acid, its relationship to Parkinson’s disease, and the possibility of reverse causation, where the disease causes a decrease in uric acid levels. The presented data support further research to understand these relationships more deeply, possibly leading to new disease treatment approaches.

14 October 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
FYF. A. Yusupov
F. A. Yusupov
MAM. Sh. Abdykadyrov
M. Sh. Abdykadyrov
Parkinson’s disease is the second most common progressive neurodegenerative disease after Alzheimer’s disease, characterized by selective loss of dopaminergic neurons in the compact part of the substantia nigra. This leads to striatal dopamine deficiency and motor symptoms. Along with this, non-motor disorders, in particular cardiovascular dysfunctions, play a significant role in the pathogenesis of Parkinson’s disease, which have a significant impact on the quality of life of patients.Neurogenic mechanisms include pathological accumulation and aggregation of alpha-synuclein with the formation of Lewy bodies and neurites, detected in both the central and peripheral autonomic nervous systems, including the heart sympathetic innervation. Additionally, non-neurogenic factors (decreased intravascular volume due to dysphagia and inadequate fluid intake, heart failure, and antiparkinsonian-induced hypotension) contribute to orthostatic hypotension and other cardiovascular events, increasing the risk of stroke and other complications.In addition to autonomic and motor manifestations, mental and cognitive impairment is of paramount importance in Parkinson’s disease. Depression, anxiety, and dementia are found in 40-50% of patients, often in the early stages of the disease, and through activation of the sympathoadrenal system, increased cortisol levels, and baroreflex dysfunction can exacerbate arrhythmias, ischemic episodes, and other cardiac events. In addition, decreased motivation and adherence to therapy with mental symptoms further increases the risk of adverse cardiovascular outcomes in this group of patients.

15 June 2025 in Bulletin of Science and Practice
Verified
Journal Article
Closed access
IMI. Murkamilov
I. Murkamilov
KAK. Aitbaev
K. Aitbaev
FYF. Yusupov
F. Yusupov
ZRZ. Raimzhanov
Z. Raimzhanov
TYT. Yusupova
T. Yusupova
IAI. Abdibaliev
I. Abdibaliev
Chronic kidney disease (CKD) is a clinical, laboratory, and instrumental syndrome that develops against the background of the gradual and irreversible loss of nephrons. A key laboratory indicator of CKD is a decrease in the glomerular filtration rate (GFR) to ≤ 60 mL/min/1.73 m². Anemia, hyperuricemia, hyperphosphatemia, and arterial hypertension are the most common conditions accompanying CKD. In the etiological structure of CKD, the leading causes include type 2 diabetes mellitus (T2DM), hypertension, chronic heart failure (CHF), and interstitial nephropathies. Patients with CKD are classified as high or very high cardiovascular risk. Common cardiovascular manifestations in CKD include diastolic dysfunction and left ventricular hypertrophy, high-grade arrhythmias, ischemic heart disease (IHD), and CHF. The pathogenesis of IHD in CKD is characterized by disturbances in lipid, calcium-phosphate, and purine metabolism. In CKD patients, anemia, proteinuria, and hypertension accelerate the development of IHD. Frequent episodes of myocardial ischemia in CKD lead to collagen accumulation and fibrosis, resulting in increased left ventricular stiffness and diastolic dysfunction. Coronary angiography in CKD patients often reveals multivessel and diffuse coronary artery lesions. In end-stage CKD, pronounced coronary artery calcification is observed. The morphological substrate of IHD in CKD is represented by athero- and arteriosclerotic coronary artery damage. Severe coronary calcification complicates stent placement, and the hypertrophied myocardium becomes highly sensitive to reduced hemoglobin levels. The article presents a clinical case of combined CKD and IHD in an elderly patient with a background of T2DM.

15 January 2025 in Bulletin of Science and Practice
Verified
Journal Article
Closed access
FYF. Yusupov
F. Yusupov
AIAkmal Iuldashev
Akmal Iuldashev
AYA. Yusupov
A. Yusupov
MAM. Abdykadyrov
M. Abdykadyrov
The microbiome of the oral cavity plays an important role in the development and progression of various somatic diseases, including stroke. Studies show that bacteria living in the oral cavity can enter the bloodstream and contribute to inflammatory processes, which increases the risk of cardiovascular disease and stroke. It was found that in 79% of the studied stroke-related blood clots, DNA of bacteria commonly found in the oral cavity, such as streptococci of the Viridans species, was found. Periodontal pathogenic microorganisms can cause chronic inflammation and contribute to the development of atherosclerosis, which is one of the main risk factors for stroke. Dysbiosis of the oral cavity is also associated with an increase in the level of proinflammatory cytokines, which can worsen the condition of blood vessels and increase the likelihood of thrombosis. Thus, maintaining oral health and timely treatment of dental diseases can have a significant impact on reducing the risk of stroke. Understanding the relationship between the oral microbiome and the state of the cardiovascular system opens up new horizons for the development of preventive measures and therapeutic approaches to the treatment of patients at high risk of stroke.

30 December 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
FYF.A. Yusupov
F.A. Yusupov
MAM.SH. Abdykadyrov
M.SH. Abdykadyrov
Objective. To systematize current data on neurogenesis and its role in the pathogenesis of neurodegenerative conditions, such as Alzheimer’s disease and Parkinson’s disease, with a focus on molecular mechanisms of regulation, the nature of disorders in neurodegeneration, and the evaluation of therapeutic approaches aimed at stimulating neurogenesis. Material and methods. Research papers published in scientific databases, mainly Scopus, PubMed, and Google Scholar, over the past 5 years were used for this review. Special attention was paid to studies on neurogenesis and its role in the pathogenesis of neurodegenerative diseases. The review included studies that met the following criteria: publications from the past five years reporting current neurogenesis data, using clearly identified experimental and clinical techniques, published in peer-reviewed international journals with a high impact factor, and providing reliable statistics to support the results. Studies with a limited sample size and insufficient statistical significance, those lacking a transparent methodology or exhibiting a low level of data reproducibility, reviews without a clear focus on neurogenesis or its connection to neurodegenerative diseases, and studies providing insufficient information on the applied technologies and analysis methods were excluded. Results. Modern research has significantly expanded the understanding of neurogenesis and its role in neurodegenerative diseases. Neurogenesis has been confirmed to occur in specific areas of the adult brain, including the hippocampus, where it is involved in cognitive processes such as learning, memory consolidation, spatial adaptation, cognitive flexibility, and regulation of affective behavior. However, the extent and functional significance of neurogenesis in different brain regions remain a matter of debate. The effect of neurodegenerative diseases on neurogenesis varies: in Alzheimer’s disease, studies in animal models demonstrate its impairment; however, data on humans are inconsistent: a decrease in neurogenesis is observed in the early stages of the disease, but in some cases, its increase is reported, likely as a compensatory mechanism. Factors influencing neurogenesis in Alzheimer’s disease include β-amyloid and tau protein accumulation, neuroinflammation, mitochondrial dysfunction, and oxidative stress. Parkinson’s disease is associated with a decrease in neurogenesis in the subventricular zone and hippocampus due to the degeneration of dopaminergic neurons and the accumulation of α-synuclein; however, deep brain stimulation is able to enhance neuronal proliferation. Therapeutic strategies include pharmacological approaches aimed at stimulating neurogenesis, such as the use of neurotrophic factors, acetylcholinesterase inhibitors, selective serotonin reuptake inhibitors, Wnt and EGFR signaling pathway modulators, uric acid, and MFG-E8, as well as non-pharmacological methods, including physical activity, enriched environment, cognitive training, electrical stimulation, and music therapy. Conclusion. Neurodegenerative diseases are a significant problem in modern healthcare, requiring an in-depth study of the mechanisms of neurogenesis and its role in pathogenesis. Despite conflicting evidence on neurogenesis in adult humans, animal model studies and cellular technologies demonstrate prospects for its therapeutic stimulation. Pharmacological and non-pharmacological methods, including the use of neurotrophic factors, electrical stimulation, and cognitive training, as well as cellular and gene therapy, are the basis of new intervention strategies. However, the issues of controlling the differentiation and integration of new neurons, as well as the ethical aspects associated with the use of stem cells, remain unresolved. Further interdisciplinary research aimed at studying the regulatory mechanisms of neurogenesis and its therapeutic potential may lead to the development of effective treatment strategies that can slow or even reverse the progression of neurodegenerative diseases. It highlights the need to integrate advanced technologies and approaches in modern neuroscience and clinical practice.